124721-03-5

Basic information

• Product Name: platinum(4+) chloride hydroxide - cyclohexanamine ammoniate (1:2:2:1:1)
• CAS NO: 124721-03-5
• Molecular Formula: C₆H₁₈Cl₂N₂O₂Pt
• Molecular Weight: 416.2093
• Mol File: 124721-03-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 134.5°C at 760 mmHg
• Flash Point: 32.2°C
• Vapor Pressure: 8.07mmHg at 25°C
• CAS DataBase Reference: platinum(4+) chloride hydroxide - cyclohexanamine ammoniate (1:2:2:1:1)(CAS DataBase Reference)
• NIST Chemistry Reference: platinum(4+) chloride hydroxide - cyclohexanamine ammoniate (1:2:2:1:1)(124721-03-5)
• EPA Substance Registry System: platinum(4+) chloride hydroxide - cyclohexanamine ammoniate (1:2:2:1:1)(124721-03-5)

Safety Data

• Hazardous Substances Data: 124721-03-5(Hazardous Substances Data)

Upstream product

• 159701-67-4 cis-dichloro-trans-ammonia(cyclohexylamine)platinum 
• 7722-84-1 dihydrogen peroxide 
• 209861-57-4 C₆H₂₀N₂O₂Pt⁽²⁺⁾ 
• 108-91-8 cyclohexylamine 

Downstream Products

• 160953-33-3 (OC-6-43)-amminedichloro(cyclohexanamine)bis((methylthio)acetato-O)platinum(IV) 
• 129580-64-9 c-t-c-Pt(IV)Cl₂(O₂C-n-C₄H₉)2(NH₃)(c-C₆H₁₁NH₂) 
• 129552-14-3 (OC-6-33)-amminedichloro(cyclohexanamine)bis(2,2-dimethylpropanoato-O)platinum(IV) 
• 160953-30-0 (OC-6-43)-amminedichloro(cyclohexanamine)bis(ethyl carbonato-O)platinum(IV) 
• 5545-17-5 N,N'-diacetyl-L-cystine 
• 1034767-14-0 trans-[Pt(OH)2(c-C₆H₁₁NH₂)(NH₃)] 
• 3384-95-0 3,4-dithia-hexane-1,2,5,6-tetracarboxylic acid 
• 4775-93-3 2,2'-dithiobispropanoic acid 
• 56-89-3 cysteine disulfide 
• 312-10-7 DL-penicillamine disulfide 
• 40055-98-9 oxidized glutathione 
• 56-89-3 L-cystine 
• 129580-63-8 (OC₆-6-12)-bis(acetato-O)amminedichloro(cyclohexylamine)platinum(IV) 
• 129580-63-8 (OC₆-6-22)-bis(acetato-O)amminedichloro(cyclohexylamine)platinum(IV) 

Relevant articles and documents

Synthesis, characterization, and antitumor activity of novel tumor-targeted platinum(IV) complexes

Four tumor-targeted platinum(IV) complexes with ammonia and cyclohexylamine as the carrier groups and biotin as the axial group were designed, synthesized, and characterized. In vitro evaluation of the antitumor activity of complexes C1–C4 against lung cancer cells (A549), liver cancer cells (SMMC-7721), breast cancer cells (MCF-7), and colon cancer cells (SW480) was carried out. Complex C3 had the best cellular activity. Compared with cisplatin, complex C3 showed good anticancer activity against A549 cell line,complex C3 (6.34±0.44) is 3 times more cytotoxic than cisplatin (19.40±0.71),and against MCF-7 cell line complex C3 (4.22±0.11) is 5.4 times more cytotoxic than cisplatin (22.96±0.58), and against SW480 cell line complex C3 (6.65±0.60) is 3.4 times more cytotoxic than cisplatin (23.15±0.22). (Table 1) Axial chloride increased the redox power of complex C3 to increase the intercellular accumulation and the introduction of mixed amine had the ability to overcome cisplatin resistance. Complex C3 works best on MCF-7, then SW480, A549, and SMMC-7721. Thus, complex C3 is targeted by the axial introduction of biotin.

A compound with anticancer activity and its preparation method

The invention provides a compound having anticancer activity, which is obtained by cooperation of Norabieta cantharidin and platinum (IV) and modification of a piperazine derivative. The compound is characterized in that a Norabieta cantharidin piperazine derivative ligand is introduced, thereby cytotoxicity of a platinum (IV) compound is reduced, and high antineoplastic activity is provided. The result of the cytotoxicity experiments shows that the provided platinum (IV) compound has less destruction to normal mice fibroblast L929, but has good killing effect to cancer cells such as human breast cancer MCF-7 cell, human cervical carcinoma HeLa cell and human lung adenocarcinoma A549 cell, so that the compound having anticancer activity is capable of reducing the system toxicity and having equal anticancer activity with cisplatin. The compound having anticancer activity has good killing effect by aiming at cisplatin resistance human lung adenocarcinoma A549/DDP cell. Therefore, the toxicity is reduced, the cisplatin resistance can be reversed, and anticancer effect of the platinum medicines can be increased.

Crystal and Molecular Structures of Asymmetric cis- and trans-Platinum(II/IV) Compounds and Their Reactions with DNA Fragments

The asymmetrically substituted platinum(II) complexes cis-Pt(NH3)(c-C5H11NH2)Cl 2 and trans-Pt(NH3)(c-C6H11-NH2)Cl 2 have been synthesized and their crystal structures have been determined. Crystals of cis-Pt(NH3)(c-C6H11NH2)Cl 2 (1) are orthorhombic, space group Pbca (no. 61) with a = 10.1994(12), b = 10.494(2), c = 18.826(2) ?, Z = 8. The structure refinement converged to R1 = 0.0518 and wR2 = 0.1143. Crystals of trans-Pt(NH3)(c-C6H11NH2)Cl 2 (2) are monoclinic, space group P21/c (no. 14) with a = 12.141(3), b = 6.0965(9), c = 19.864(3) ?, β= 118.71(2)°, Z = 4. The structure refinement converged to R1 = 0.0711 and wR2 = 0.1846. In addition, the Pt(IV) analogues with axial hydroxide ligands have been synthesized. Also the corresponding bis(carboxylato)-platinum(IV) compound of formula trans,cis,cis-Pt(NH3)(c-C6H11NH 2)Cl2(OOCCH3)2 has been obtained by conversion of the hydroxide with acetic anhydride. Reactions of these platinum complexes with 9-methylhy-poxanthine and guanosine-5′-monophosphate (5′-GMP) have been studied in significant detail. The course of the reactions was followed by NMR spectroscopy, and 1H and 195Pt techniques were used to identify the formation of the products. It was found that the Pt(II) compounds easily react with the bases at the N7 position, whereas the Pt(IV) compounds react very slowly (for trans,cis,cis-Pt(NH3)(c-C6H11NH 2)Cl2(OOCCH3)2) or not at all (for trans,trans,trans-Pt(NH3)(c-C6H11NH 2)Cl2(OH)2). Only in the presence of glutathione does a reaction of the latter with 5′-GMP takes place. In this case a major product was found to be the reduced trans-Pt(II) complex with one molecule of 5′-GMP and one molecule of S-bonded glutathione.